A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Documentation on acute GVHD is limited due to its complex nature and the relatively small population affected. The rarity of systematic clinical studies and the lack of identified genetic factors contribute to this knowledge gap. Additionally, the clinical features can vary significantly among individuals, making it challenging to establish a comprehensive understanding of the condition. Despite these limitations, ongoing research offers hope for better insights and treatment options.
To navigate your care for acute GVHD, consider seeking a hematologist or oncologist with specific expertise in transplant-related complications. These specialists can provide tailored management strategies for your condition. Additionally, while no specific patient organizations are identified, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of GVHD.
There are currently several orphan drugs approved for the treatment of acute GVHD, including abatacept, belumosudil, remestemcel-L-rknd, and ruxolitinib. Additionally, numerous drugs are in development, such as anti-CD3 monoclonal antibodies and various stem cell therapies. With 6255 active clinical trials available, patients may have opportunities to participate in research that could inform future treatment options. For more information, you can search for trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=acute%20graft%20versus%20host%20disease.
Actionable guidance for navigating care for acute graft versus host disease
To navigate your care for acute GVHD, consider seeking a hematologist or oncologist with specific expertise in transplant-related complications. These specialists can provide tailored management strategies for your condition. Additionally, while no specific patient organizations are identified, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of GVHD.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 39 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning acute graft versus host disease
Updated Feb 8, 2026
A recent case report highlights the occurrence of acute graft-versus-host disease following deceased-donor liver transplantation. This finding may inform future clinical practices and patient management strategies in transplant settings.